Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123856 | 0.91 | ROCK2 (0.45) | KMT2AMEN1HTT | |
| SCHEMBL4116191 | 0.75 | CNR1 (0.54) | CNR1KMT2AMEN1HTT | |
| SCHEMBL3929530 | 0.70 | CNR1 (0.52) | CNR1KMT2AMEN1HTTMTNR1A | |
| SCHEMBL13853575 | 0.67 | CNR1 (0.67) | CNR1HTTCA1CA2CA7 | |
| SCHEMBL2205978 | 0.67 | MTNR1A (0.65) | CNR1KMT2AMEN1HTTCA1 | |
| SCHEMBL4123853 | 0.67 | ROCK2 (0.51) | CNR1KMT2AMEN1 | |
| SCHEMBL18997630 | 0.66 | MTNR1A (0.62) | CNR1HTTCA1CA2MTNR1A | |
| SCHEMBL3150231 | 0.66 | P2RY1 (0.66) | — | |
| SCHEMBL12935919 | 0.66 | MTNR1A (0.60) | CNR1HTTCA1CA2CA7 | |
| SCHEMBL875811 | 0.66 | MTNR1A (0.63) | CNR1HTTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | CNR1 2880/4885KMT2A 2034/4885MEN1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.